Takara Bio Inc. (4974.T)
JPY 781.0
(2.36%)
JPY 781.0
(2.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3 Billion JPY | -85.38% |
| 2022 | 20.54 Billion JPY | -28.93% |
| 2021 | 28.9 Billion JPY | 107.15% |
| 2020 | 13.95 Billion JPY | 122.38% |
| 2019 | 6.27 Billion JPY | 14.85% |
| 2018 | 5.46 Billion JPY | 53.67% |
| 2017 | 3.55 Billion JPY | 11.02% |
| 2016 | 3.2 Billion JPY | 20.06% |
| 2015 | 2.66 Billion JPY | 15.86% |
| 2014 | 2.3 Billion JPY | 17.81% |
| 2013 | 1.95 Billion JPY | 15.55% |
| 2012 | 1.69 Billion JPY | -64.56% |
| 2011 | 4.77 Billion JPY | 14.19% |
| 2010 | 4.17 Billion JPY | 11.06% |
| 2009 | 3.76 Billion JPY | 0.11% |
| 2008 | 3.75 Billion JPY | 3.33% |
| 2007 | 3.63 Billion JPY | 22.24% |
| 2006 | 2.97 Billion JPY | 185.88% |
| 2005 | 1.04 Billion JPY | 3.48% |
| 2004 | 1 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.63 Billion JPY | -161.31% |
| 2023 Q4 | 2.66 Billion JPY | 348.14% |
| 2023 Q3 | -1.07 Billion JPY | -208.81% |
| 2023 Q2 | 987 Million JPY | 133.33% |
| 2023 Q1 | 423 Million JPY | -62.83% |
| 2023 FY | 3 Billion JPY | -85.38% |
| 2022 Q3 | 8.53 Billion JPY | 34.74% |
| 2022 FY | 20.54 Billion JPY | -28.93% |
| 2022 Q1 | 4.53 Billion JPY | -49.45% |
| 2022 Q2 | 6.33 Billion JPY | 39.59% |
| 2022 Q4 | 1.13 Billion JPY | -86.66% |
| 2021 Q2 | 5.6 Billion JPY | -34.14% |
| 2021 Q3 | 5.82 Billion JPY | 3.93% |
| 2021 FY | 28.9 Billion JPY | 107.15% |
| 2021 Q4 | 8.97 Billion JPY | 54.2% |
| 2021 Q1 | 8.5 Billion JPY | 64.77% |
| 2020 Q4 | 5.16 Billion JPY | 2.1% |
| 2020 Q2 | 3.04 Billion JPY | 339.11% |
| 2020 FY | 13.95 Billion JPY | 122.38% |
| 2020 Q1 | 693 Million JPY | -71.06% |
| 2020 Q3 | 5.05 Billion JPY | 66.12% |
| 2019 FY | 6.27 Billion JPY | 14.85% |
| 2019 Q2 | 784 Million JPY | -65.17% |
| 2019 Q1 | 2.25 Billion JPY | 10.83% |
| 2019 Q3 | 844 Million JPY | 7.65% |
| 2019 Q4 | 2.39 Billion JPY | 183.77% |
| 2018 Q2 | 1.07 Billion JPY | -30.12% |
| 2018 Q4 | 2.03 Billion JPY | 151.05% |
| 2018 Q3 | 809 Million JPY | -25.02% |
| 2018 Q1 | 1.54 Billion JPY | -20.7% |
| 2018 FY | 5.46 Billion JPY | 53.67% |
| 2017 Q3 | 920 Million JPY | 115.96% |
| 2017 Q2 | 426 Million JPY | 62.6% |
| 2017 Q1 | 262 Million JPY | -45.19% |
| 2017 Q4 | 1.94 Billion JPY | 111.63% |
| 2017 FY | 3.55 Billion JPY | 11.02% |
| 2016 Q2 | 734 Million JPY | 14.15% |
| 2016 Q3 | 1.34 Billion JPY | 83.51% |
| 2016 FY | 3.2 Billion JPY | 20.06% |
| 2016 Q4 | 478 Million JPY | -64.51% |
| 2016 Q1 | 643 Million JPY | -47.42% |
| 2015 Q2 | 573 Million JPY | 416.22% |
| 2015 FY | 2.66 Billion JPY | 15.86% |
| 2015 Q4 | 1.22 Billion JPY | 60.92% |
| 2015 Q3 | 760 Million JPY | 32.64% |
| 2015 Q1 | 111 Million JPY | -89.32% |
| 2014 Q3 | 638 Million JPY | 13.93% |
| 2014 Q4 | 1.03 Billion JPY | 62.85% |
| 2014 FY | 2.3 Billion JPY | 17.81% |
| 2014 Q1 | 65 Million JPY | -93.79% |
| 2014 Q2 | 560 Million JPY | 761.54% |
| 2013 Q3 | 454 Million JPY | -44.09% |
| 2013 Q4 | 1.04 Billion JPY | 130.4% |
| 2013 FY | 1.95 Billion JPY | 15.55% |
| 2013 Q1 | -358 Million JPY | -136.38% |
| 2013 Q2 | 812 Million JPY | 326.82% |
| 2012 Q2 | 1.3 Billion JPY | -1.51% |
| 2012 Q4 | 984 Million JPY | 151.09% |
| 2012 Q1 | 1.32 Billion JPY | 65.59% |
| 2012 FY | 1.69 Billion JPY | -64.56% |
| 2012 Q3 | -1.92 Billion JPY | -247.25% |
| 2011 Q3 | 1.47 Billion JPY | -1.21% |
| 2011 Q1 | 1.01 Billion JPY | 54.98% |
| 2011 Q4 | 802 Million JPY | -45.44% |
| 2011 FY | 4.77 Billion JPY | 14.19% |
| 2011 Q2 | 1.48 Billion JPY | 47.04% |
| 2010 Q2 | 1.15 Billion JPY | 13.82% |
| 2010 FY | 4.17 Billion JPY | 11.06% |
| 2010 Q4 | 653 Million JPY | -51.95% |
| 2010 Q3 | 1.35 Billion JPY | 17.87% |
| 2010 Q1 | 1.01 Billion JPY | 175.27% |
| 2009 Q2 | 1.25 Billion JPY | 57.29% |
| 2009 Q4 | 368 Million JPY | -72.48% |
| 2009 Q3 | 1.33 Billion JPY | 6.79% |
| 2009 FY | 3.76 Billion JPY | 0.11% |
| 2009 Q1 | 796 Million JPY | 110.03% |
| 2008 Q3 | 1.23 Billion JPY | 8.08% |
| 2008 Q2 | 1.13 Billion JPY | 0.0% |
| 2008 FY | 3.75 Billion JPY | 3.33% |
| 2008 Q4 | 379 Million JPY | -69.19% |
| 2007 FY | 3.63 Billion JPY | 22.24% |
| 2006 FY | 2.97 Billion JPY | 185.88% |
| 2005 FY | 1.04 Billion JPY | 3.48% |
| 2004 FY | 1 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | -403.165% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 704.386% |
| GNI Group Ltd. | 13.1 Billion JPY | 77.092% |
| Linical Co., Ltd. | 725.72 Million JPY | -313.794% |
| Trans Genic Inc. | 89.43 Million JPY | -3257.708% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 310.596% |
| Soiken Holdings Inc. | -610 Million JPY | 592.289% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 488.616% |
| AnGes, Inc. | -11.96 Billion JPY | 125.093% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 367.934% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 131.524% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | -2779.222% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 447.403% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 368.85% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 337.956% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 476.053% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 990.134% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 349.177% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 324.843% |
| PeptiDream Inc. | 6.77 Billion JPY | 55.662% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 255.597% |
| Ribomic Inc. | -1.11 Billion JPY | 369.039% |
| SanBio Company Limited | -4.53 Billion JPY | 166.16% |
| Healios K.K. | -3.37 Billion JPY | 188.872% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 359.982% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 315.499% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 314.041% |
| StemRIM | -2.07 Billion JPY | 244.653% |
| CellSource Co., Ltd. | 1.22 Billion JPY | -145.845% |
| FunPep Company Limited | -994 Million JPY | 402.113% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 437.886% |
| Stella Pharma Corporation | -760.3 Million JPY | 494.976% |
| TMS Co., Ltd. | -943.25 Million JPY | 418.366% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 487.288% |
| Cuorips Inc. | -588.48 Million JPY | 610.292% |
| K Pharma,Inc. | 366.05 Million JPY | -720.364% |
| ReproCELL Incorporated | -409.29 Million JPY | 833.704% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -27044.536% |
| StemCell Institute Inc. | 413.75 Million JPY | -625.785% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | -1978.1% |
| CellSeed Inc. | -697.77 Million JPY | 530.367% |